Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?

Détails

ID Serval
serval:BIB_F98ADB31F4D5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
Périodique
World journal of urology
Auteur(s)
Schardt J., Roth B., Seiler R.
ISSN
1433-8726 (Electronic)
ISSN-L
0724-4983
Statut éditorial
Publié
Date de publication
09/2019
Peer-reviewed
Oui
Volume
37
Numéro
9
Pages
1759-1765
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
For 40 years cisplatin-based chemotherapy has been administered to patients with muscle-invasive bladder cancer (MIBC). The best evidence of its efficacy is found in the context of neoadjuvant chemotherapy (NAC). However, the benefit to the patient is modest, with an improvement in 5-year overall survival of only 5-8%. Approximately 60% of patients still have muscle-invasive disease at cystectomy despite NAC. Selecting patients based on the likelihood of response appears to be a promising strategy to improve on this modest benefit. To realize this promise, researchers are investigating biomarkers for identifying responders and non-responders prior to NAC.
In this review, we discuss a number of tissue- and liquid-based biomarkers associated with the response to NAC.
We elaborate biomarkers at the methylation, DNA, RNA and protein levels and give their current status in clinical trials and/or their implementation in daily clinical practice. In particular, detection of alterations in DNA damage repair pathways as well as molecular subtypes seems to be a promising method for identifying responders to NAC. Furthermore, we illustrate liquid-based biomarkers. Circulating tumor DNA (ctDNA) in patient blood and urine appear to offer an elegant way for biological characterization of MIBC. Recent data show that the presence of ctDNA is limited in patients with localized MIBC being considered for NAC. At this disease stage, ctDNA in patient urine may be more promising for the genomic characterization of MIBC. However, ctDNA in blood or urine has not yet been rigorously investigated in this clinical context.
Mots-clé
Antineoplastic Agents/therapeutic use, Cisplatin/therapeutic use, Humans, Neoplasm Invasiveness, Time Factors, Treatment Outcome, Urinary Bladder Neoplasms/drug therapy, Urinary Bladder Neoplasms/pathology, Cisplatin resistance, Gene expression analysis, Molecular subtypes, Muscle-invasive bladder cancer, Neoadjuvant chemotherapy, Second-line treatment
Pubmed
Web of science
Création de la notice
08/01/2021 16:06
Dernière modification de la notice
09/01/2021 7:26
Données d'usage